Lack of mitochondrial toxicity in CEM cells treated with carbovir

Antiviral Research

Volumn 34, Issue 3, 1997, Pages 131-136

  Parker, William B ^a   Shaddix, S C ^a   Vince, Robert ^b   Bennett Jr , L Lee ^a  

^a SOUTHERN RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

1592U89; Carbovir; Delayed cytotoxicity; Lactic acid; Mitochondrial DNA synthesis

Indexed keywords

CARBOVIR; LACTIC ACID; MITOCHONDRIAL DNA; ZALCITABINE;

ARTICLE; CELL CULTURE; CONTROLLED STUDY; CYTOTOXICITY; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTI-HIV AGENTS; CELL LINE; DIDEOXYNUCLEOSIDES; DNA, MITOCHONDRIAL; DRUG EVALUATION, PRECLINICAL; HUMANS; LACTIC ACID; MITOCHONDRIA; PRODRUGS; ZALCITABINE;

EID: 0030914625     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-3542(97)01033-4     Document Type: Article

References (27)

1. Chen, C.-H. and Cheng, Y.-C. (1989) Delayed cytotoxicity and selective loss of mitochondrial DNA in cells treated with the anti-human immunodeficiency virus compound 2′,3′-dideoxycytidine. J. Biol. Chem. 264, 11 934-11 937.
2. Medina, D.J., Tsai, C.-H., Hsiung, G.D. and Cheng, Y.-C. (1994) Comparison of mitochondrial morphology, mitochondrial DNA content, and cell viability in cultured cells treated with three anti-human immunodeficiency virus dideoxynucleosides. Antimicrob. Agents Chemother. 38, 1824-1828.
3. Dalakas, M.C., Illa, I., Pezeshkpour, G.H., Laukaitis, J.P., Cohen, B. and Griffin, J.L. (1990) Mitochondrial myopathy caused by long-term zidovudine therapy. New Engl. J. Med. 322, 1098-1105.
4. Parker, W.B. and Cheng, Y.-C. (1994) Mitochondrial toxicity of antiviral nucleoside analogs. J. NIH Res. 6, 57-61.
5. Ono, K., Nakane, H., Herdewijn, P., Balzarini, J. and De Clercq, E. (1989) Differential inhibitory effects of several pyrimidine 2′,3′-dideoxynucleoside 5′-triphosphates on the activities of reverse transcriptase and various cellular DNA polymerases. Mol. Pharmacol. 35, 578-583.
6. Starnes, M.C. and Cheng, Y.-C. (1987) Cellular metabolism of 2′,3′-dideoxycytidine, a compound active against human immunodeficiency virus in vitro. J. Biol. Chem. 262, 988-991.
7. Chang, C.-N., Skalskii, V., Zhou, J.H. and Cheng, Y.-C. (1992) Biochemical pharmacology of (+)- and (-)-2′,3′-dideoxy-3′-thiacytidine as anti-hepatitis B virus agents. J. Biol. Chem. 267, 22414-22420.
8. Hart, G.J., Orr, D.C., Penn, C.R., Figueiredo, H.T., Gray, N.M., Boehme, R.E. and Cameron, J.M. (1992) Effects of (-)-2′-deoxy-3′-thiacytidine (3TC) 5′-triphosphate on human immunodeficiency virus reverse transcriptase and mammalian DNA polymerases alpha, beta and gamma. Antimicrobial Agents Chemother. 36, 1688-1694.
9. Vince, R., Hua, M., Brownell, J., Daluge, S., Lee, F., Shannon, W.M., Lavelle, G.C., Qualls, J., Weislow, O.S., Kiser, R., Canonico, P.G., Schultz, R.H., Narayanan, V.L., Mayo, J.G., Shoemaker, R.H. and Boyd, M.R. (1988) Potent and selective activity of a new carbocyclic nucleoside analog (carbovir: NSC 614846) against human immunodeficiency virus in vitro. Biochem. Biophys. Res. Commun. 156, 1046-1053.
10. Vince, R. and Brownell, J. (1990) Resolution of racemic carbovir and selective inhibition of human immunodeficiency virus by the (-) enantiomer. Biochem. Biophys. Res. Commun. 168, 912-916.
11. Carter, S.G., Kessler, J.A. and Rankin C.D. (1990) Activities of (-)-carbovir and 3′-azido-3′-deoxythymidine against human immunodeficiency virus in vitro. Antimicrob. Agents Chemother. 34, 1297-1300.
12. Coates, J.A.V., Inggall, H.J., Pearson, B.A., Penn, C.R. Storer, R., Williamson, C. and Cameron, J.M. (1991) Carbovir: the (-) enantiomer is a potent and selective antiviral agent against human immunodeficiency virus in vitro. Antiviral Res. 15, 161-168.
13. Johnson, M.A. and A. Fridland.(1989) Phosphorylation of 2′,3′-dideoxyinosine by cytosolic 5′-nucleotidase of human lymphoid cells. Mol. Pharmacol. 36, 291-295.
14. Bondoc, L.L., Jr., Shannon, W.M., Secrist, III, J.A., Vince, R. and Fridland, A. (1990) Metabolism of the carbocyclic nucleoside analogue carbovir, an inhibitor of human immunodeficiency virus, in human lymphoid cells. Biochem. 29, 9839-9843.
15. Parker, W.B., Shaddix, S.C., Bowdon, B.J., Vince, R. Shannon, W.M. and Bennett, Jr., L.L. (1993) Metabolism of carbovir, a potent inhibitor of human immunodeficiency virus type 1 replication, and its effect on cellular metabolism. Antimicrob. Agents Chemother. 37, 1004-1009.
16. Miller, W. H., Daluge, S.M., Garvey, E.P., Hopkins, S. Reardon, J.E., Boyd, F.L. and Miller, R.L. (1992) Phosphorylation of carbovir enantiomers by cellular enzymes determines the stereoselectively of antiviral activity. J. Biol. Chem. 267, 21 220-21 224.
17. White, E.L., Parker, W.B., Macy, L.J., Shaddix, S.C., McCaleb, G., Secrist, III, J.A., Vince, R. and Shannon, W.M. (1989) Comparison of the effect of carbovir, AZT, and dideoxynucleoside triphosphates on the activity of human immunodeficiency virus reverse transcriptase and selected human polymerases. Biochem. Biophys. Res. Commun. 161, 393-398.
18. Parker, W.B., White, E.L., Shaddix, S.C., Ross, L.J., Buckheit Jr., R.W., Germany, J.M., Secrist III, J.A., Vince, R. and Shannon, W.M. (1991) Mechanism of inhibition of human immunodeficiency virus type I reverse transcriptase and human DNA polymerases α, β, and γ by the 5′-triphosphates of carbovir, 3′-azido-3′-deoxythymidine, 2′,3′-dideoxyguanosine and 3′-deoxythymidine. A novel RNA template for the evaluation of antiretroviral drugs. J. Biol. Chem. 266, 1754-1762.
19. Miller, W. H., Daluge, S.M., Garvey, E.P., Hopkins, S. Reardon, J.E., Boyd, F.L. and Miller, R.L. (1992) Phosphorylation of carbovir enantiomers by cellular enzymes determines the stereoselectively of antiviral activity. J. Biol. Chem. 267, 21 220-21 224.
20. Orr, D.C., Figueiredo, H.T., Mo, C.-L., Penn, C.R. and Cameron, J.M. (1992) DNA chain termination activity and inhibition of human immunodeficiency virus reverse transcriptase by carbocyclic 2′,3′-didehydro-2′,3′-dideoxyguanosine triphosphate. J. Biol. Chem. 267, 4177-4182.
21. Faletto, M.B., Miller, W.H., Garvey, E.P., St. Clair, M.H., Hazen, R.J., Daluge, S.M. and Good, S.S. (1995) Unique purine crossover activation pathway for the potent anti- HIV agent 1592U89. Eighth Int. Conf. Antiviral Res. 26, A262.
22. Merkenschlager, M., Kardamakis, D., Rawle, F.C., Spurr, N. and Beverly, P.C.L. (1988) Rate of incorporation of radiolabelled nucleosides does not necessarily reflect the metabolic state of cells in culture: effects of latent mycoplasma contamination. Immunology 63, 125-131.
23. Higuchi, Y. and Linn, S. (1995) Purification of all forms of HeLa cell mitochondrial DNA and assessment of damage to it caused by hydrogen peroxide treatment of mitochondria or cells. J. Biol. Chem. 270, 7950-7956.
24. Yeom, Y.-H., Remmel, R.P., Huang, S.-H., Hua, M., Vince, R. and Zimmerman, C.L. (1989) Pharmacokinetics and bioavailability of carbovir, a carbocyclic nucleoside active against human immunodeficiency virus, in rats. Antimicrob. Agents Chemother. 33, 171-175.
25. El Dareer, S.M., Tillery, K.F., Rose, L.M., Struck, R.F. and Hill, D.L. (1990) Disposition and metabolism of carbovir in mice dosed intravenously or orally. Drug Metabolism Disposition 18, 842-845.
26. 3. 3rd Conf. Retroviruses Opportunistic Infections, 89.
27. Hughes, W., Mcdowell, J., Adams, L., Flynn, P., Hetherington, S., Kline, M., Shenep, J., Yogev, R. and Lafon, S. (1996) Evaluation of the novel nucleoside 1592U89 in a phase I safety and pharmacokinetics (PK) study in HIV-infected infants and children. 3rd Conf. Retroviruses Opportunistic Infections, 115.